Abstract
Objective To study the role of GBA variants in the risk for isolated rapid-eye-movement (REM)-sleep behavior disorder (iRBD) and conversion to overt neurodegeneration.
Methods A total of 4,147 individuals were included: 1,061 iRBD patients and 3,086 controls. GBA was fully sequenced using molecular inversion probes and Sanger sequencing. We analyzed the effects of GBA variants on the risk for iRBD, age at onset (AAO) and conversion rates.
Results GBA variants were found in 9.5% of iRBD patients compared to 4.1% in controls (odds ratio [OR]=2.45, 95% CI=1.87–3.22, p=1×10−10). The estimated OR for mild p.N370S variant carriers was 3.69, 95% CI=1.90–7.14, p=3.5×10−5, while for severe variant carriers it was 17.55, 95% CI=2.11–145.9, p=0.0015. Carriers of severe GBA variants had an average AAO of 52.8 years, 7-8 years earlier than those with mild variants or non-carriers (p=0.029). Of the GBA variant carriers with available data, 52.5% had converted, compared to 35.6% in non-carriers (p=0.011), with a trend for faster conversion among severe GBA variant carriers. However, the results on AAO and conversion were based on small numbers and should be taken with caution.
Conclusions GBA variants robustly and differentially increase the risk of iRBD. The rate of conversion to neurodegeneration is also increased and may be faster among severe GBA variant carriers, although confirmation will be required in larger samples. Screening for RBD in healthy carriers of GBA variants should be studied as a potential way to identify GBA variant carriers who will develop a synucleinopathy in the future.
Competing Interest Statement
Lynne Krohn – Reports no conflict of interests Jennifer A. Ruskey – Reports no conflict of interests Uladislau Rudakou - Reports no conflict of interests Etienne Leveille – Reports no conflict of interests Farnaz Asayesh – Reports no conflict of interests Michele T.M. Hu – Received consultancy fees from Roche and Biogen Pharmaceuticals Isabelle Arnulf – Received fees for speaking engagements from UCB pharma, consultancy for Roche, Novartis, and Ono Pharma. Yves Dauvilliers – Reports no conflict of interests Birgit Högl – Received consultancy fees from Axovant, benevolent Bio, Takeda, Roche, ono, and received speaker honoraria from Eli Lilly, Mundipharma, UCB, Abbvie, Inspire, Lundbeck. Ambra Stefani – Reports support for research from Axovant Christelle Charley Monaca – Reports no conflict of interests Abril Beatriz – Reports no conflict of interests Giuseppe Plazzi – Reports no conflict of interests Elena Antelmi – Reports no conflict of interests Luigi Ferini-Strambi – Reports no conflict of interests Anna Heidbreder – Received honoraria for lectures from UCB, Bioprojet, Servier, Medice and consultancy fees from UCB. Bradley F. Boeve – Dr. Boeve has served as an investigator for clinical trials sponsored by Biogen and Alector. He serves on the Scientific Advisory Board of the Tau Consortium. He receives research support from the NIH, the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, the Little Family Foundation, and the LBD Functional Genomics Program. Alberto J. Espay – Received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Abbvie, Adamas, Acadia, Acorda, Neuroderm, Neurocrine, Impax/Amneal, Sunovion, Lundbeck, Osmotica Pharmaceutical, and USWorldMeds; publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer; and honoraria from USWorldMeds, Lundbeck, Acadia, Sunovion, the American Academy of Neurology, and the Movement Disorders Society. Valérie Cochen De Cock – Reports no conflict of interests Brit Mollenhauer – Has received honoraria for consultancy from Roche, Biogen, UCB and Sun Pharma Advanced research Company. BM is member of the executive steering committee of the Parkinson Progression Marker Initiative and PI of the Systemic Synuclein Sampling Study of the Michael J. Fox Foundation for Parkinson’s Research and has received research funding from the Deutsche Forschungsgemeinschaft (DFG), EU (Horizon2020), Parkinson Fonds Deutschland, Deutsche Parkinson Vereinigung and the Michael J. Fox Foundation for Parkinson’s Research. Friederike Sixel-Döring – Honoraria for lectures from Abbott, Desitin, Grünenthal, Licher MT, STADA Pharm, UCB. Seminar fees from Boston Scientific, Licher MT. Serves on an advisory board for STADA Pharm. No conflict of interest with the presented study. Claudia Trenkwalder – Honoraria for lectures from UCB, Grünenthal, Otsuka and consultancy fees from Britannia Pharmaceuticals and Roche. Karel Sonka – Reports no conflict of interests David Kemlink – Reports no conflict of interests Michela Figorilli – Reports no conflict of interests Monica Puligheddu – Reports no conflict of interests Femke Dijkstra – Reports no conflict of interests Mineke Viaene – Reports no conflict of interests Wolfgang Oertel – Reports no conflict of interests related to the study. He received consultancy or speaker fees from Adamas, Abbvie, Desitin, Novartis and Roche. Marco Toffoli – Reports no conflict of interests Gian Luigi Gigli – Reports no conflict of interests Mariarosaria Valente – Reports no conflict of interests Jean-François Gagnon – Reports research funding from the Canadian Institutes for Health Research (CIHR). Alex Desautels – Received grants from Flamel Ireland, Pfized, Biron, Canopy Growth, as well as fees for speaking engagements from Biogen and from consultancy from UCB pharma. Jacques Y. Montplaisir – Reports no conflict of interests Ronald B. Postuma – Reports grants and Fonds de la Recherche en Sante, as well as grants from the the Canadian Institute of Health Research, The Parkinson Society of Canada, the Weston-Garfield Foundation, the Michael J. Fox Foundation, and the Webster Foundation, as well as personal fees from Takeda, Roche, Teva Neurosciences, Novartis Canada, Biogen, Boehringer Ingelheim, Theranexus, GE HealthCare, azz Pharmaceuticals, Abbvie, Jannsen, Otsuko, Phytopharmics, and Inception Sciences Guy A. Rouleau – Reports no conflict of interests Ziv Gan-Or – Received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Inceptions Sciences (now Ventus), Denali and Deerfield.
Funding Statement
This work was financially supported by Parkinson Canada, the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canadian Glycomics Network (GlycoNet), the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives (HBHL) program, the Canadian Institutes for Health Research (CIHR), Weston Foundation, Fonds de recherche du Québec - Santé (FRQS) Chercheurs-boursiers. The Oxford Discovery study is funded by the Monument Trust Discovery Award from Parkinson’s UK and supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust and University of Oxford, the NIHR Clinical Research Network and the Dementias and Neurodegenerative Diseases Research Network (DeNDRoN).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of interest: Lynne Krohn – Reports no conflict of interests
Jennifer A. Ruskey – Reports no conflict of interests
Uladislau Rudakou - Reports no conflict of interests
Etienne Leveille – Reports no conflict of interests
Farnaz Asayesh – Reports no conflict of interests
Michele T.M. Hu – Received consultancy fees from Roche and Biogen Pharmaceuticals
Isabelle Arnulf – Received fees for speaking engagements from UCB pharma, consultancy for Roche, Novartis, and Ono Pharma.
Yves Dauvilliers – Reports no conflict of interests
Birgit Högl – Received consultancy fees from Axovant, benevolent Bio, Takeda, Roche, ono, and received speaker honoraria from Eli Lilly, Mundipharma, UCB, Abbvie, Inspire, Lundbeck.
Ambra Stefani – Reports support for research from Axovant
Christelle Charley Monaca – Reports no conflict of interests
Abril Beatriz – Reports no conflict of interests
Giuseppe Plazzi – Reports no conflict of interests
Elena Antelmi – Reports no conflict of interests
Luigi Ferini-Strambi – Reports no conflict of interests
Anna Heidbreder – Received honoraria for lectures from UCB, Bioprojet, Servier, Medice and consultancy fees from UCB.
Bradley F. Boeve – Dr. Boeve has served as an investigator for clinical trials sponsored by Biogen and Alector. He serves on the Scientific Advisory Board of the Tau Consortium. He receives research support from the NIH, the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, the Little Family Foundation, and the LBD Functional Genomics Program.
Alberto J. Espay – Received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Abbvie, Adamas, Acadia, Acorda, Neuroderm, Neurocrine, Impax/Amneal, Sunovion, Lundbeck, Osmotica Pharmaceutical, and USWorldMeds; publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer; and honoraria from USWorldMeds, Lundbeck, Acadia, Sunovion, the American Academy of Neurology, and the Movement Disorders Society.
Valérie Cochen De Cock – Reports no conflict of interests
Brit Mollenhauer – Has received honoraria for consultancy from Roche, Biogen, UCB and Sun Pharma Advanced research Company. BM is member of the executive steering committee of the Parkinson Progression Marker Initiative and PI of the Systemic Synuclein Sampling Study of the Michael J. Fox Foundation for Parkinson’s Research and has received research funding from the Deutsche Forschungsgemeinschaft (DFG), EU (Horizon2020), Parkinson Fonds Deutschland, Deutsche Parkinson Vereinigung and the Michael J. Fox Foundation for Parkinson’s Research.
Friederike Sixel-Döring – Honoraria for lectures from Abbott, Desitin, Grünenthal, Licher MT, STADA Pharm, UCB. Seminar fees from Boston Scientific, Licher MT. Serves on an advisory board for STADA Pharm. No conflict of interest with the presented study.
Claudia Trenkwalder – Honoraria for lectures from UCB, Grünenthal, Otsuka and consultancy fees from Britannia Pharmaceuticals and Roche.
Karel Sonka – Reports no conflict of interests
David Kemlink – Reports no conflict of interests
Michela Figorilli – Reports no conflict of interests
Monica Puligheddu – Reports no conflict of interests
Femke Dijkstra – Reports no conflict of interests
Mineke Viaene – Reports no conflict of interests
Wolfgang Oertel – Reports no conflict of interests related to the study. He received consultancy or speaker fees from Adamas, Abbvie, Desitin, Novartis and Roche.
Marco Toffoli – Reports no conflict of interests
Gian Luigi Gigli – Reports no conflict of interests
Mariarosaria Valente – Reports no conflict of interests
Jean-François Gagnon – Reports research funding from the Canadian Institutes for Health Research (CIHR).
Alex Desautels – Received grants from Flamel Ireland, Pfized, Biron, Canopy Growth, as well as fees for speaking engagements from Biogen and from consultancy from UCB pharma.
Jacques Y. Montplaisir – Reports no conflict of interests
Ronald B. Postuma – Reports grants and Fonds de la Recherche en Sante, as well as grants from the the Canadian Institute of Health Research, The Parkinson Society of Canada, the Weston-Garfield Foundation, the Michael J. Fox Foundation, and the Webster Foundation, as well as personal fees from Takeda, Roche, Teva Neurosciences, Novartis Canada, Biogen, Boehringer Ingelheim, Theranexus, GE HealthCare, azz Pharmaceuticals, Abbvie, Jannsen, Otsuko, Phytopharmics, and Inception Sciences
Guy A. Rouleau – Reports no conflict of interests
Ziv Gan-Or – Received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Inceptions Sciences (now Ventus), Denali and Deerfield.
Data Availability
Anonymized data is available upon request from the corresponding author
